摘要
目的观察并探讨生长抑素与奥美拉唑联合治疗重症急性胰腺炎(severe acute pancrcatitis,SAP)的临床疗效。方法将2003年1月~2012年5月间来我院住院治疗的120例重症急性胰腺炎患者随机分成试验组和对照组,后者仅给予禁食、解痉、持续胃肠解压、质子泵抑制剂(PPI)抑酸、积极预防感染以及维持机体酸碱平衡等常规治疗,而前者在此基础上还给以生长抑素与奥美拉唑联合治疗,且两组治疗疗程均为7天。并比较两组患者在腹痛腹胀缓解时间、肠道功能恢复时间、血、尿淀粉酶恢复正常的时间、平均住院时间以及临床疗效(治愈和死亡)和并发症发生率等方面的差异性。结果试验组患者腹痛腹胀缓解时间、肠道功能恢复时间、血、尿淀粉酶恢复正常的时间、平均住院时间均明显低于对照组;试验组治愈率为93.3%,而对照组为70.0%,两者差异具有统计学意义;而试验组的病死率为1.7%,明显低于对照组的8.3%,且组间差异均有统计学意义(P<0.05)。结论生长抑素与奥美拉唑联合治疗重症急性胰腺炎能够显著改善SAP患者的临床症状,降低并发症的发生率和病死率,临床疗效显著。
Objective To study the clinical efficacy of somatostatin and omeprazole for treating severe acute pancrcatitis.Methods 120 patients of SAP were randomly divided into two groups,60 each groups.The control group only given routine treatment,but the treatment group was given the combination therapy of somatostatin and omeprazole with the treatment durations of 7 days.And we will analysis the clinical index which including alleviation time of abnormal pain and intestinal function recovery time,serum and urine amylase returned to normal time and the clinical healing time.Results The alleviation time of abnormal pain and intestinal function recovery time,serum and urine amylase returned to normal time and the clinical healing time were significant better than those in the control group(P〈0.05).The recovery rate of the treatment group was 93.3% while the control group was only 70.0%;and the mortality of the treatment group was only 1.7%,much lower than the control group's 8.3%(P〈0.05).Conclusion The combination therapy of somatostatin and omeprazole can increase clinical efficacy in patients with SAP.
出处
《肝胆外科杂志》
2012年第6期417-419,共3页
Journal of Hepatobiliary Surgery